60 related articles for article (PubMed ID: 38565996)
1. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Bergin K; Wellard C; Augustson B; Cooke R; Blacklock H; Harrison SJ; Ho J; King T; Quach H; Mollee P; Walker P; Moore E; McQuilten Z; Wood E; Spencer A;
Bone Marrow Transplant; 2021 Oct; 56(10):2533-2543. PubMed ID: 34011965
[TBL] [Abstract][Full Text] [Related]
2. MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma.
Cui QQ; Li ZH; Ma YP
Leuk Lymphoma; 2024 May; ():1-8. PubMed ID: 38814179
[TBL] [Abstract][Full Text] [Related]
3. Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.
Wang Y; Xu P; Chen Y; Fan Q; Li J; Zhao W; Mi J; Yan H
Mol Clin Oncol; 2016 Jan; 4(1):107-113. PubMed ID: 26870367
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis.
Chen YH; Fogel L; Sun AY; Yang C; Patel R; Chang WC; Chen PH; Jhou HJ; Chen YC; Dai MS; Lee CH
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786328
[TBL] [Abstract][Full Text] [Related]
5. Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation.
Barajas Ordonez F; Wolleschak D; Zeller Y; Hinnerichs M; Rodríguez-Feria P; Aghayev A; Mikusko M; Borggrefe J; Mougiakakos D; Surov A
Leuk Lymphoma; 2024 Jun; 65(6):825-832. PubMed ID: 38384127
[TBL] [Abstract][Full Text] [Related]
6. Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).
Shibayama H; Itagaki M; Handa H; Yokoyama A; Saito A; Kosugi S; Ota S; Yoshimitsu M; Tanaka Y; Kurahashi S; Fuchida SI; Iino M; Shimizu T; Moriuchi Y; Toyama K; Mitani K; Tsukune Y; Kada A; Tamura H; Abe M; Iwasaki H; Kuroda J; Takamatsu H; Sunami K; Kizaki M; Ishida T; Saito T; Matsumura I; Akashi K; Iida S
Int J Hematol; 2024 Jun; 119(6):707-721. PubMed ID: 38548963
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
Jin X; Jiang X; Li H; Shen K; Liu S; Chen M; Yang C; Han B; Zhuang J
Acta Haematol; 2024 Apr; ():1-10. PubMed ID: 38626745
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.
Li X; Yu Y; Yu H; Chen M; Zhang X; Wu Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):193. PubMed ID: 38619663
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
Coffey DG; Maura F; Gonzalez-Kozlova E; Diaz-Mejia JJ; Luo P; Zhang Y; Xu Y; Warren EH; Dawson T; Lee B; Xie H; Smith E; Ciardiello A; Cho HJ; Rahman A; Kim-Schulze S; Diamond B; Lesokhin A; Kazandjian D; Pugh TJ; Green DJ; Gnjatic S; Landgren O
Nat Commun; 2023 Sep; 14(1):5335. PubMed ID: 37660077
[TBL] [Abstract][Full Text] [Related]
10. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; Rosiñol L; Puig N; Pico-Picos MA; Medina-González L; Martínez-López J; Paiva B; Cedena MT; Oriol A; Ríos-Tamayo R; Blanchard MJ; Jarque I; Bargay J; Moraleda JM; Carrillo-Cruz E; Sureda A; Krsnik I; González E; Casado LF; Martí JM; Encinas C; De Arriba F; Palomera L; Sampol A; González-Montes Y; Motlló C; De La Cruz J; Alonso R; Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J; Hernández MT
Haematologica; 2023 Nov; 109(6):1909-17. PubMed ID: 38031761
[TBL] [Abstract][Full Text] [Related]
11. The patients with multiple myeloma were infected with COVID-19 during autologous stem cell transplantation: case report and literature review.
Su C; Huang L; Liang L; Ou L; Lu G; Wang C; He Y; Zeng R; Li Y; Zhou H; Xiao L
Infect Agent Cancer; 2024 May; 19(1):25. PubMed ID: 38802946
[TBL] [Abstract][Full Text] [Related]
12. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
14. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
Fan H; Wang W; Zhang Y; Wang J; Cheng T; Qiu L; Wang X; Xia Z; An G
Cancer Biol Med; 2023 Jan; 20(1):77-87. PubMed ID: 36647781
[TBL] [Abstract][Full Text] [Related]
15. Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy.
Hughes CFM; Shah GL; Paul BA
Front Oncol; 2024; 14():1373548. PubMed ID: 38601770
[TBL] [Abstract][Full Text] [Related]
16. Historical Perspective of High-Dose Therapy Followed by Autologous Stem Cell Transplantation in Multiple Myeloma.
Cohen I; Vaxman I; Gertz MA
Acta Haematol; 2024 May; ():. PubMed ID: 38710160
[TBL] [Abstract][Full Text] [Related]
17. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
